EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Form 2 Diabetes
Sufferers with form 2 diabetes handled with the SGLT2 inhibitor empagliflozin right thru the landmark EMPA-REG OUTCOME trial had a solidly lowered favor to both beginning up insulin treatment or intensify fresh insulin treatment, in comparison with these given placebo,…